Results 171 to 180 of about 64,954 (254)

Islet Autoantibodies in Adult With Pituitary and Ovarian Autoimmunity: Implications for Type 1 Diabetes Screening

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5827-5833, July 2026.
ABSTRACT Purpose Type 1 diabetes is a chronic autoimmune disease characterised by progressive pancreatic β‐cell destruction and the early appearance of islet autoantibodies (islet‐AAb) during the pre‐symptomatic phases. Given the growing interest in screening and prevention of type 1 diabetes, this study aimed to assess the prevalence of pancreatic ...
Giuseppe Bellastella, Michela di Nuzzo, Miriam Longo, Paolo Cirillo, Antonietta Maio, Nicole Di Martino, Silvia Angelino, Paola Caruso, Lorenzo Scappaticcio, Maria Teresa Vietri, Maria Ida Maiorino, Katherine Esposito   +11 more
wiley   +1 more source

Tau and β-Amyloid Relevant Pathology as a Central Therapeutic Target in Alzheimer's Disease. [PDF]

Biomolecules
Strużyńska L, Adamiak K, Sidoryk-Węgrzynowicz M.   +2 more
europepmc   +1 more source

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives

European Journal of Haematology, Volume 117, Issue 1, Page 42-54, July 2026.
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Targeted Therapy in Hepatobiliary Pancreatic Cancer (HPC): Advantages and Advancements of Antibody Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. [PDF]

Int J Mol Sci
Deb Nath T, Mukherjee A, Chauhan SC, Bandyopadhyay D.   +3 more
europepmc   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

European Journal of Haematology, Volume 117, Issue 1, Page 144-153, July 2026.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello, Andrea Aroldi, Alessia Castellino, Lara Mannelli, Elia Boccellato, Serena Rosati, Luisa Verga, Umberto Vitolo   +7 more
wiley   +1 more source

Obinutuzumab after anti-rituximab antibody-associated treatment failure in membranous nephropathy: a case report. [PDF]

Front Immunol
Guo J, Zhong A, Wu D, Liu Y, Chen Y, Xu Y, Xu R, Wan Q.   +7 more
europepmc   +1 more source

From the Proteome to Therapeutics: A Multi‐Database Approach to Drug Discovery in Periodontitis—An Exploratory Pilot Study

Journal of Clinical Periodontology, Volume 53, Issue 7, Page 990-1004, July 2026.
ABSTRACT Introduction This explanatory pilot study presents a workflow to identify approved drugs, which could be repurposed for periodontitis therapy using salivary proteomics combined with drug‐target database screening. Methods Proteomic analyses of saliva using LC–MS/MS were conducted in two independent settings: a cohort (sub‐study I, N = 187) and
Taisir Bozo, Annette Murr, Birte Holtfreter, Sebastian‐Edgar Baumeister, Peter Meisel, Uwe Völker, Werner Weitschies, Henry Völzke, Philipp Kanzow, Elke Hammer, Manuela Gesell Salazar, Thomas Kocher   +11 more
wiley   +1 more source

Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background We aimed to investigate and characterise DILI due to approved therapies for inflammatory bowel disease (IBD). Methods Using the Drug‐Induced Liver Injury Network (DILIN) prospective study, we evaluated definite, highly likely, or probable DILI attributed to IBD therapies, including use for non‐IBD indications (but excluding ...
Harish Gopalakrishna, Jiezhun Gu, Yi‐Ju Li, Huiman Barnhart, Dina Halegoua‐DeMarzio, Herbert L. Bonkovsky, A. Sidney Barritt, Jean P. Molleston, Naga P. Chalasani, Marwan Ghabril   +9 more
wiley   +1 more source

Discovery, development, and characterization of SPY002 and SPY072, two novel extended half-life monoclonal antibodies targeting TL1A: in vitro properties, in vivo pharmacology, pharmacokinetics, and preclinical safety. [PDF]

MAbs
Siegel M, Zhu E, Rios D, Kang BH, McNally J, Kennedy M, Hew K, Patel P, Ballew O, Giles DH, Lewis EMA, LaFountaine J, Oh J, Friedman JR, Rose MJ, Shaheen H, Spencer AG.   +16 more
europepmc   +1 more source